MedTrace Logo

The Role of Methylphenidate on Performance in the Cold

NCT04283877 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-02-09

No results posted yet for this study

Summary

The purpose is to study the effects of dopamine activity, using methylphenidate ingestion, on exercise and cognitive function over the course of a progressive cooling protocol. The investigators hypothesize that methylphenidate will minimize the previously reported impairment in exercise performance and cognitive function with mild hypothermia and cold stress (air temperature: 0˚C) compared to placebo, suggesting that dopamine activity preserves exercise and cognitive capacity with mild hypothermia.

Conditions

  • Hypothermia
  • Exercise Test
  • Cognition

Interventions

DRUG

Methylphenidate

3 x 10 mg oral tablets. Single acute dose for all participants

DRUG

Placebo oral tablet

3 x 10 mg oral lactose tablet for all participants

Sponsors & Collaborators

  • Brock University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-15
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04283877 on ClinicalTrials.gov